Valuing Celegene’s CVR
Anyone ever look at the HBS case study? Should Tanaka buy more CVRs, hold, or sell her CVRs? Thanks!
Trending Content - Investment Banking Forum
| +219 | Downfall of Qatalyst | 42 | 9h |
| +167 | UBS IB 26Q2 a Disaster! Advisory Revenue Down 23%, Capital MarketsDown 5% | 22 | 3d |
| +111 | UBS Americas IB: The Kids’ Table of Wall Street | 15 | 13h |
| +81 | Lincoln International Return Offers | 42 | 1d |
| +52 | so confused about 28 SA timeline | 27 | 6d |
| +51 | London IB BB is a challenge | 31 | 1h |
| +37 | momentum of Rx groups | 11 | 1d |
| +36 | Fired during interview | 6 | 17h |
| +33 | [WSO MODS] Please Delete This BS Host Books Spam! | 2 | 5d |
| +27 | VP Lifestyle at Top BB Coverage Groups | 13 | 9h |
Career Resources
